Evidence map›Paper›PMID 41602412›Full record

ArticleFrontiers in oncology2025

Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review.

Huami Ye, Linlin Huang, Changqian Chen, Shihua Huang, Lianjie Hu, Ling Wang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huami YeDepartment of Hematology, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
Linlin HuangPathological Diagnosis Center, Sichuan Kingmed Center for Clinical Laboratory CO, Ltd, Chengdu, Sichuan, China.
Changqian ChenDepartment of Hematology, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
Shihua HuangDepartment of Hematology, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
Lianjie HuDepartment of Hematology, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
Ling WangPathological Diagnosis Center, Sichuan Kingmed Center for Clinical Laboratory CO, Ltd, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Composite lymphoma has been rarely reported due to its low incidence. The treatment of composite lymphoma depends on the specific lymphoma subtypes involved. No standardized therapeutic regimen has been established. We tried to treat the patient with Sintilimab+AVD for composite Hodgkin lymphoma and follicular lymphoma, after which the patient was able to maintain a normal quality of life and achieved partial remission (PR). To the best of our knowledge, this is the first attempt to use the PD-1 inhibitor combined with the AVD regimen successfully for the treatment of composite Hodgkin lymphoma and follicular lymphoma.

Indexed as

composite lymphomafollicular lymphomaHodgkin lymphomaPD-1 inhibitorstreatment

Identifiers

PMID41602412
PMCPMC12833697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.